< IP News

USPTO Terminates Challenge to Patents on CRISPR Genome-Editing Technology

The Patent Trial and Appeal Board (the “PTAB”) of the United States Patent and Trademark Office (“USPTO”) halted a challenge to patents of the Broad Institute of Harvard and MIT directed to CRISPR genome-editing technology by terminating an interference proceeding initiated by the University of California. The CRISPR technology relates to an ancient bacterial immune system that has been repurposed to edit DNA. In its decision, the PTAB found that even though the earlier patent application of the University  of California disclosed the CRISPR technology for use generally, it would not subsequently have been obvious to arrive at the Broad Institute’s technique for using CRISPR to edit the genomes of mouse and human cells. The PTAB accordingly terminated the interference proceedings.  A full copy of the decision can be found here.

Information made available on this website in any form is for information purposes only. It is not, and should not be taken as legal advice. You should not rely on, or take or fail to take any action, based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Oyen Wiggs Green & Mutala LLP professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Expertise

Related Industries